Suppr超能文献

描述和评估起始高度致吐性化疗的患者中止吐药物的使用不足。

Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy.

机构信息

UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, CB# 7573, Chapel Hill, NC, 27599, USA.

出版信息

Support Care Cancer. 2019 Dec;27(12):4525-4534. doi: 10.1007/s00520-019-04730-3. Epub 2019 Mar 26.

Abstract

BACKGROUND

Patients initiating highly emetic chemotherapy (HEC) are at a 90% risk of chemotherapy-induced nausea and vomiting (CINV). Despite guideline-concordant antiemetic prescribing preventing CINV in up to 80% of patients, studies suggest that guideline-concordant antiemetic regimen use by patients initiating HEC is sub-optimal. However, these studies have been limited to single-site or single-cancer type with limited generalizability. The objective of this study was to describe antiemetic fill regimens and to assess predictors of underuse in the USA.

METHODS

Our study population was adult patients under the age of 65 with cancer initiating intravenous HEC between 2013 and 2015 with employer-sponsored insurance in the IBM Watson/Truven MarketScan Commercial Claims database (N = 31,923). Descriptive statistics were used to explain antiemetic prescribing patterns, including antiemetic underuse. Modified Poisson regression was used to identify factors associated with antiemetic underuse.

RESULTS

Among individuals initiating HEC, 49% underused guideline-concordant antiemetics. Most classified as under-using lacked an NK1 fill. While dexamethasone and 5HT3A uptake was over 80%, olanzapine use was minimal. Having lower generosity for prescription and medical benefits (paying more versus less than 20% out-of-pocket) increased the underuse risk by 3% and 4% (RR,1.03; 95% CI,1.01-1.05; P = 0.01 and RR,1.04; CI, 1.00-1.09; P = 0.03), respectively. Additionally, compared to receiving chemotherapy in the physician office setting, patients were at a 28% (RR, 1.28; 95% CI, 1.25-1.30; P < 0.0001) higher underuse risk in the outpatient hospital setting.

CONCLUSION

Antiemetic underuse is high in patients initiating HEC, potentially leading to avoidable CINV events. We found that insurance generosity has a minimal effect on antiemetic guideline concordance in this population, suggesting discordance may be the result of site of care as well as gaps in provider knowledge or accountability.

摘要

背景

接受高度致吐化疗(HEC)的患者有 90%的风险会发生化疗引起的恶心和呕吐(CINV)。尽管符合指南的止吐药物治疗可预防多达 80%的患者发生 CINV,但研究表明,接受 HEC 治疗的患者使用符合指南的止吐方案并不理想。然而,这些研究仅限于单站点或单一癌症类型,其普遍性有限。本研究的目的是描述止吐药物的使用情况,并评估美国患者未充分使用止吐药物的预测因素。

方法

我们的研究人群是在 IBM Watson/Truven MarketScan 商业索赔数据库中年龄在 65 岁以下、在 2013 年至 2015 年期间接受静脉注射 HEC 治疗且有雇主赞助保险的癌症患者(N=31923)。采用描述性统计方法解释止吐药物的使用模式,包括止吐药物的使用不足。采用校正泊松回归分析确定与止吐药物使用不足相关的因素。

结果

在接受 HEC 治疗的患者中,有 49%的患者未充分使用符合指南的止吐药物。大多数被归类为未充分使用的患者缺乏 NK1 类药物。尽管地塞米松和 5-HT3A 类药物的使用率超过 80%,但奥氮平的使用率却很低。处方和医疗福利的慷慨程度(自付费用低于或高于 20%)分别增加了 3%和 4%的未充分使用风险(RR,1.03;95%CI,1.01-1.05;P=0.01 和 RR,1.04;CI,1.00-1.09;P=0.03)。此外,与在医生办公室接受化疗相比,患者在门诊医院接受化疗时的未充分使用风险增加了 28%(RR,1.28;95%CI,1.25-1.30;P<0.0001)。

结论

在接受 HEC 治疗的患者中,止吐药物的使用不足情况很高,可能导致可避免的 CINV 事件。我们发现,在这一人群中,保险的慷慨程度对止吐药物治疗的指南一致性影响很小,这表明这种不一致可能是护理地点以及提供者知识或责任方面的差距所致。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验